Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in gene editing dealmaking
2.1. Introduction
2.2. Gene editing partnering over the years
2.3. Most active gene editing dealmakers
2.4. Gene editing partnering by deal type
2.5. Gene editing partnering by therapy area
2.6. Deal terms for gene editing partnering
2.6.1 Gene editing partnering headline values
2.6.2 Gene editing deal upfront payments
2.6.3 Gene editing deal milestone payments
2.6.4 Gene editing royalty rates

Chapter 3 – Leading gene editing deals
3.1. Introduction
3.2. Top gene editing deals by value

Chapter 4 – Most active gene editing dealmakers
4.1. Introduction
4.2. Most active gene editing dealmakers
4.3. Most active gene editing partnering company profiles

Chapter 5 – Gene editing contracts dealmaking directory
5.1. Introduction
5.2. Gene editing contracts dealmaking directory

Chapter 6 – Gene editing dealmaking by technology type

Appendices
Appendix 1 – Gene editing deals by company A-Z
Appendix 2 – Gene editing deals by stage of development
Appendix 3 – Gene editing deals by deal type
Appendix 4 – Gene editing deals by therapy area
Appendix 5 – Deal type definitions
Appendix 6 – Further reading

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Gene editing partnering since 2010
Figure 2: Active gene editing dealmaking activity since 2010
Figure 3: Gene editing partnering by deal type since 2010
Figure 4: Gene editing partnering by disease type since 2010
Figure 5: Gene editing deals with a headline value
Figure 6: Gene editing deals with an upfront value
Figure 7: Gene editing deals with a milestone value
Figure 8: Gene editing deals with a royalty rate value
Figure 9: Top gene editing deals by value since 2010
Figure 10: Most active gene editing dealmakers since 2010